Respiratory

Children's solution in drops, to help prevent and treat influenza and other respiratory tract infections. If discomfort persists, consult your doctor.

Natural vitamin C in delicious chewable tablets, made with rose hips. This product is not a medicine. The consumption of this product is the responsibility of the person recommending it and the person using it.

Wellmune-based children's shot, orange flavor This product is not a medicine. The consumption of this product is the responsibility of the person recommending it and the person using it.

Wellmune Gummies for Children This product is not a medicine. The consumption of this product is the responsibility of the person recommending it and the person using it.

Effective relief for common cold symptoms. Stop the flu and cough with X-tri D, relieving nasal congestion, body aches, runny nose, and fever.

XL-3 Antigripal is an analgesic, antipyretic, antihistamine, and decongestant for allergic rhinitis. It is the ideal medication for relieving discomfort.

Zinc-based dietary supplement in capsules If discomfort persists, consult your doctor.

Zinc Capsules This product is not a medicine. The consumption of this product is the responsibility of the person recommending it and the person using it.

Amifarin (Dicloxacillin) is a semi-synthetic antibiotic of the penicillin family, indicated for the treatment of bacterial infections caused by organisms sensitive to dicloxacillin. Each bottle contains 60 ml of powder for oral suspension, equivalent to 250 mg/5 ml of dicloxacillin. This medicine is only available with a medical prescription. Wandel Laboratory

AMIKACIN-AMSA INJECTION 500 Amikacin injection belongs to a class of medications called aminoglycoside antibiotics. It works by eliminating bacteria. Antibiotics such as amikacin injection do not work against colds, influenza, or any other viral infection. C/1 Therapeutic Indications Amikacin Short-term treatment of serious infections caused by gram-sensitive microorganisms: Pseudomonas, E. coli, Proteus (indole-positive and indole-negative), Providencia, Klebsiella, Enterobacter, Serratia, and Acinetobacter (Mima-Herellea). Short-term treatment of serious infections caused by susceptible strains of microorganisms such as: septicemia (including neonatal sepsis); severe respiratory tract infections; CNS infections (meningitis); intra-abdominal infections (including peritonitis); complicated and recurrent urinary tract infections, where treatment is not possible with other less toxic antibiotics; Skin, bone, soft tissue, and joint infections; burn infections; postoperative infections (including post-vascular surgery).

Therapeutic Indications Cefaclor Otitis media due to: S. pneumoniae, H. influenzae, staphylococci, S. pyogenes, and M. catarrhalis; lower respiratory tract infection, pneumonia due to: S. pneumoniae, H. influenzae, S. pyogenes, and M. catarrhalis; upper respiratory tract infection, pharyngitis and tonsillitis due to: S. pyogenes and M. catarrhalis; urinary tract infection, cystitis and pyelonephritis due to: E. coli, P. mirabilis, Klebsiella, and coagulase-causing staphylococci; skin and soft tissue infection due to: S. aureus and S. pyogenes. Sinusitis. Gonococcal urethritis. Laboratorios Maver

Useful in the treatment of respiratory tract infections, bacterial sinusitis, otitis media, skin and soft tissue infections, bone and joint infections, genitourinary tract infections, including acute prostatitis, and dental infections.

Clarithromycin is useful for the treatment of: Upper respiratory tract infections (tonsillitis, pharyngitis, sinusitis, otitis). Lower respiratory tract infections (bronchitis, pneumonia). Therapeutic indications for Clarithromycin: - Oral, in immediate-release and modified-release formulations: Adults and children ≥12 years: pharyngitis, tonsillitis, sinusitis (diagnosed), acute bronchitis, acute exacerbation of chronic bronchitis, bacterial pneumonia (community-acquired), mild-to-moderate skin and soft tissue infections, folliculitis, cellulitis, erysipelas. - Oral, in immediate-release formulations: Adults and children ≥12 years: localized or disseminated infection caused by M. avium or M. intracellulare, localized infection caused by M. chelonae, M. fortuitum, and M. kansaii. Gastric or duodenal ulcer associated with H. pylori (in conjunction with appropriate anti-ulcer medication). Prevention of disseminated M. avium complex infection in high-risk HIV patients (CD4 lymphocytes ≤ 50/mm³). Children > 12 months to 11 years: streptococcal pharyngitis, bacterial bronchitis and pneumonia, acute otitis media, impetigo, folliculitis, cellulitis, abscesses. - IV: Adults: parenteral treatment of streptococcal pharyngitis or tonsillitis if first-line treatment with beta-lactams is not possible or there is demonstrated susceptibility to S. pyogenes; diagnosed acute bacterial sinusitis; acute exacerbation of chronic bronchitis; mild-to-moderate skin and soft tissue infections if beta-lactams are not appropriate.

Therapeutic Indications Clarithromycin - Oral, in immediate-release and modified-release formulations: adults and children ≥12 years: pharyngitis, tonsillitis, sinusitis (diagnosed), acute bronchitis, acute exacerbation of chronic bronchitis, bacterial pneumonia (community-acquired), mild-to-moderate skin and soft tissue infections, folliculitis, cellulitis, erysipelas. - Oral, in immediate-release formulations: adults and children ≥12 years: localized or disseminated infection caused by M. avium or M. intracellulare, localized infection caused by M. chelonae, M. fortuitum, and M. kansaii. Gastric or duodenal ulcer associated with H. pylori (in conjunction with an appropriate anti-ulcer agent). Prevention of disseminated M. avium complex infection in high-risk HIV-positive patients (CD4 lymphocytes ≤ 50/mm³). Children > 12 months to 11 years: streptococcal pharyngitis, bacterial bronchitis and pneumonia, acute otitis media, impetigo, folliculitis, cellulitis, abscesses. - IV: Adults: parenteral treatment of streptococcal pharyngitis or tonsillitis if first-line treatment with beta-lactams is not possible or there is demonstrated susceptibility to S. pyogenes; diagnosed acute bacterial sinusitis; acute exacerbation of chronic bronchitis; mild-to-moderate skin and soft tissue infections if beta-lactams are not appropriate.

Dexamethasone 8 mg/ml injectable solution: Treatment of cerebral edema secondary to brain tumors, head trauma, neurosurgery, brain abscesses, or bacterial meningitis. Treatment of traumatic shock. Treatment of severe acute asthma or status asthmaticus. Initial parenteral treatment of severe acute extensive dermatological diseases such as erythroderma, pemphigus vulgaris, or acute eczema. Initial parenteral treatment of active phases of collagenoses such as systemic lupus erythematosus, especially visceral forms. Treatment of severe infectious diseases (e.g., typhoid fever, brucellosis, tuberculosis), only as adjunctive therapy to appropriate anti-infective therapy. Prophylaxis and treatment of nausea and vomiting induced by cytostatics and after surgical interventions within the context of antiemetic regimens. Short-term adjunctive treatment during acute episodes or exacerbations of rheumatic diseases. Dexamethasone 40 mg/5 ml injectable solution: Treatment of cerebral edema secondary to brain tumors and head trauma. Treatment of traumatic shock. Treatment of anaphylactic shock (as post-primary epinephrine injection therapy).

ENT, respiratory, dental, gastrointestinal, genitourinary, skin and soft tissue, neurological, surgical, trauma, bacterial meningitis and sepsis infections.